Dr. Schuh commented, "Sorrento Therapeutics is excited to join with QuikByte as we develop and commercialize our proprietary technology for the generation of fully human monoclonal antibodies."
Glenn L. Halpryn stated "We are pleased that QuikByte has this opportunity to enter into the growing pharmaceutical field of human antibodies with an experienced team led by Drs. Schuh and Ji."
About Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. provides a broad, generally applicable platform for the generation of fully human monoclonal antibodies based on its proprietary technology. Sorrento intends to become a leading technology provider and developer of fully human monoclonal antibodies for research, diagnostic and therapeutic use.
About QuikByte Software, Inc.
QuikByte Software, Inc. is a publicly traded company with no active operations.
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects, the merger and the other transactions contemplated by the merger ag
|SOURCE QuikByte Software, Inc.|
Copyright©2009 PR Newswire.
All rights reserved